Remicade® in moderate to severe plaque psoriasis

被引：0
|
作者：
Ortonne, J. -P. [1 ]
机构：
[1] CHU Nice, Serv Dermatol, Nice, France
来源：
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE | 2006年 / 133卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1S13 / 1S17
页数：5
相关论文
共 50 条
  • [1] Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade®)
    Del Pilar Valdes A, Maria
    Schroeder H, Francisca
    Roizen G, Vicky
    Honeyman M, Juan
    Sanchez M, Leonardo
    REVISTA MEDICA DE CHILE, 2006, 134 (03) : 326 - 331
  • [2] Contemporary Management of Moderate to Severe Plaque Psoriasis
    Wu, Jashin J.
    AMERICAN JOURNAL OF MANAGED CARE, 2017, 23 (21): : S403 - S416
  • [3] Spotlight on Ustekinumab in Moderate To Severe Plaque Psoriasis
    Croxtall, Jamie D.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2012, 13 (02) : 135 - 137
  • [4] Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
    Garnock-Jones, Karly P.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2015, 16 (04) : 323 - 330
  • [5] Risankizumab in moderate-to-severe plaque psoriasis
    Serrano, Linda
    Maloney, Victoria
    Gordon, Kenneth B.
    IMMUNOTHERAPY, 2019, 11 (16) : 1357 - 1370
  • [6] Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
    Syed, Yahiya Y.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (01) : 147 - 158
  • [7] Guselkumab: A Review in Moderate to Severe Plaque Psoriasis
    Zaina T. Al-Salama
    Lesley J Scott
    American Journal of Clinical Dermatology, 2018, 19 : 907 - 918
  • [8] Guselkumab: A Review in Moderate to Severe Plaque Psoriasis
    Al-Salama, Zaina T.
    Scott, Lesley J.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (06) : 907 - 918
  • [9] Familial aggregation of moderate to severe plaque psoriasis
    Di Lernia, V.
    Ficarelli, E.
    Lallas, A.
    Ricci, C.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2014, 39 (07) : 801 - 805
  • [10] Brodalumab: A Review in Moderate to Severe Plaque Psoriasis
    Hannah A. Blair
    Drugs, 2018, 78 : 495 - 504
12345